Singapore, April 24 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
Curie Oncology(Farrer)
National Cancer Centre
National University Hospital
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Toh Chee Keong
Dr Ravindran Kanesvaran
Dr Alvin Wong Seng Cheong
Dr Puey Ling Chia
Published by HT Digital Content Services with permission from Health Daily D...